Nano-X Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming the medical imaging landscape through an integrated preventive healthcare platform, has announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering. The offering is expected to generate approximately $8 million in gross proceeds before fees and expenses, providing the company with additional capital to advance its mission of expanding access to early disease detection.
Under the terms of the agreement, Nano-X will sell 8 million ordinary shares, or prefunded warrants in lieu thereof, together with warrants to purchase up to an additional 8 million ordinary shares. The combined purchase price is set at $1.00 per share and accompanying warrant. The warrants will carry an exercise price of $1.15 per share, become exercisable six months after issuance, and will expire five years after the closing date. The offering is expected to close on or about Aug. 7, 2026, subject to customary closing conditions.
The company intends to use the net proceeds for working capital and general corporate purposes, which could include advancing its proprietary technologies and scaling its operations. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction, a role that underscores the institutional confidence in Nano-X's strategic direction.
This financing comes at a pivotal time for Nano-X, as the company continues to develop and commercialize its comprehensive ecosystem designed to lower barriers to medical imaging adoption. The Nanox ecosystem includes the Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of algorithms that augment routine CT imaging interpretation to identify early signs of chronic disease; Nanox.CLOUD, a secure platform for data management and advanced analytics; and Nanox.MARKETPLACE, which, along with USARAD Holdings, provides access to remote radiology and cardiology experts. Additionally, Nanox Health IT offers RIS, PACS, AI, dictation, and secure infrastructure solutions to streamline workflows.
The significance of this offering extends beyond the immediate capital infusion. It signals continued investor confidence in Nano-X's vision to drive the world's transition to preventive healthcare. By integrating imaging hardware, AI-driven analytics, cloud infrastructure, clinical expertise, and health IT, Nano-X aims to enhance the efficiency of routine imaging workflows and support earlier detection of disease, potentially improving patient outcomes on a global scale.
The company's focus on affordability and scalability is particularly relevant in a healthcare environment where access to advanced diagnostic tools remains uneven. Nano-X's approach could democratize medical imaging, making it more accessible in both traditional hospital settings and underserved communities. The proceeds from this offering may accelerate the development and deployment of these technologies, although the company has not specified the exact allocation beyond working capital and general corporate purposes.
Investors and industry observers will likely monitor the closing of this offering and the company's subsequent use of funds as indicators of its execution strategy. With the additional capital, Nano-X is better positioned to pursue its strategic objectives, including potential expansions of its product lineup and market reach. The involvement of a single long-term institutional investor also suggests a patient capital base, which may support the company through the regulatory and commercialization milestones ahead.
For more detailed information on the offering, the full press release is available at https://ibn.fm/5fNi8.
